Which clinical sign of Parkinson's disease best reflects the nigrostriatal lesion?
Identifieur interne : 002569 ( Ncbi/Merge ); précédent : 002568; suivant : 002570Which clinical sign of Parkinson's disease best reflects the nigrostriatal lesion?
Auteurs : F J Vingerhoets [Canada] ; M. Schulzer ; D B Calne ; B J SnowSource :
- Annals of neurology [ 0364-5134 ] ; 1997.
English descriptors
- KwdEn :
- MESH :
- diagnostic imaging : Parkinson Disease.
- physiopathology : Parkinson Disease.
- Aged, Corpus Striatum, Female, Humans, Male, Middle Aged, Substantia Nigra, Tomography, Emission-Computed.
Abstract
Clinical scales, based on the major signs of Parkinson's disease (PD), are commonly used to assess the effect of symptomatic treatment of PD. With the appearance of therapy aiming to rescue or protect the nigrostriatal neurons in PD, it becomes essential to define which of these signs best reflects the underlying neuronal deficit. Fluorodopa positron emission tomography has been shown to correlate with postmortem nigral cell counts. We correlated the major signs of PD with positron emission tomography results in 35 PD patients. We found that in the "practically defined off" state, (1) Purdue pegboard scores correlated best with the nigrostriatal dopaminergic deficit; (2) of the subscales of the modified Columbia score, the bradykinesia subscale correlated best; (3) rigidity and postural disturbance correlated less highly than bradykinesia, and their inclusion in a multiple regression did not improve the correlation of pegboard or bradykinesia scores alone; and (4) tremor did not correlate with the nigrostriatal dopaminergic deficit. We conclude that pegboard and bradykinesia scores represent the best clinical measures for studying the effect of treatment on the evolution of the nigrostriatal lesion of PD. Inclusion of other clinical signs provides additional information only for the study of functional impairments.
DOI: 10.1002/ana.410410111
PubMed: 9005866
Links toward previous steps (curation, corpus...)
- to stream PubMed, to step Corpus: 001845
- to stream PubMed, to step Curation: 001845
- to stream PubMed, to step Checkpoint: 001845
Links to Exploration step
pubmed:9005866Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Which clinical sign of Parkinson's disease best reflects the nigrostriatal lesion?</title><author><name sortKey="Vingerhoets, F J" sort="Vingerhoets, F J" uniqKey="Vingerhoets F" first="F J" last="Vingerhoets">F J Vingerhoets</name><affiliation wicri:level="1"><nlm:affiliation>Neurodegenerative Disorders Centre and TRIUMF, University of British Columbia, Vancouver, Canada.</nlm:affiliation><country xml:lang="fr">Canada</country><wicri:regionArea>Neurodegenerative Disorders Centre and TRIUMF, University of British Columbia, Vancouver</wicri:regionArea><wicri:noRegion>Vancouver</wicri:noRegion></affiliation></author><author><name sortKey="Schulzer, M" sort="Schulzer, M" uniqKey="Schulzer M" first="M" last="Schulzer">M. Schulzer</name></author><author><name sortKey="Calne, D B" sort="Calne, D B" uniqKey="Calne D" first="D B" last="Calne">D B Calne</name></author><author><name sortKey="Snow, B J" sort="Snow, B J" uniqKey="Snow B" first="B J" last="Snow">B J Snow</name></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="1997">1997</date><idno type="RBID">pubmed:9005866</idno><idno type="pmid">9005866</idno><idno type="doi">10.1002/ana.410410111</idno><idno type="wicri:Area/PubMed/Corpus">001845</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">001845</idno><idno type="wicri:Area/PubMed/Curation">001845</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">001845</idno><idno type="wicri:Area/PubMed/Checkpoint">001845</idno><idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">001845</idno><idno type="wicri:Area/Ncbi/Merge">002569</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Which clinical sign of Parkinson's disease best reflects the nigrostriatal lesion?</title><author><name sortKey="Vingerhoets, F J" sort="Vingerhoets, F J" uniqKey="Vingerhoets F" first="F J" last="Vingerhoets">F J Vingerhoets</name><affiliation wicri:level="1"><nlm:affiliation>Neurodegenerative Disorders Centre and TRIUMF, University of British Columbia, Vancouver, Canada.</nlm:affiliation><country xml:lang="fr">Canada</country><wicri:regionArea>Neurodegenerative Disorders Centre and TRIUMF, University of British Columbia, Vancouver</wicri:regionArea><wicri:noRegion>Vancouver</wicri:noRegion></affiliation></author><author><name sortKey="Schulzer, M" sort="Schulzer, M" uniqKey="Schulzer M" first="M" last="Schulzer">M. Schulzer</name></author><author><name sortKey="Calne, D B" sort="Calne, D B" uniqKey="Calne D" first="D B" last="Calne">D B Calne</name></author><author><name sortKey="Snow, B J" sort="Snow, B J" uniqKey="Snow B" first="B J" last="Snow">B J Snow</name></author></analytic><series><title level="j">Annals of neurology</title><idno type="ISSN">0364-5134</idno><imprint><date when="1997" type="published">1997</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Aged</term><term>Corpus Striatum</term><term>Female</term><term>Humans</term><term>Male</term><term>Middle Aged</term><term>Parkinson Disease (diagnostic imaging)</term><term>Parkinson Disease (physiopathology)</term><term>Substantia Nigra</term><term>Tomography, Emission-Computed</term></keywords><keywords scheme="MESH" qualifier="diagnostic imaging" xml:lang="en"><term>Parkinson Disease</term></keywords><keywords scheme="MESH" qualifier="physiopathology" xml:lang="en"><term>Parkinson Disease</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Aged</term><term>Corpus Striatum</term><term>Female</term><term>Humans</term><term>Male</term><term>Middle Aged</term><term>Substantia Nigra</term><term>Tomography, Emission-Computed</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Clinical scales, based on the major signs of Parkinson's disease (PD), are commonly used to assess the effect of symptomatic treatment of PD. With the appearance of therapy aiming to rescue or protect the nigrostriatal neurons in PD, it becomes essential to define which of these signs best reflects the underlying neuronal deficit. Fluorodopa positron emission tomography has been shown to correlate with postmortem nigral cell counts. We correlated the major signs of PD with positron emission tomography results in 35 PD patients. We found that in the "practically defined off" state, (1) Purdue pegboard scores correlated best with the nigrostriatal dopaminergic deficit; (2) of the subscales of the modified Columbia score, the bradykinesia subscale correlated best; (3) rigidity and postural disturbance correlated less highly than bradykinesia, and their inclusion in a multiple regression did not improve the correlation of pegboard or bradykinesia scores alone; and (4) tremor did not correlate with the nigrostriatal dopaminergic deficit. We conclude that pegboard and bradykinesia scores represent the best clinical measures for studying the effect of treatment on the evolution of the nigrostriatal lesion of PD. Inclusion of other clinical signs provides additional information only for the study of functional impairments.</div></front></TEI><pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">9005866</PMID><DateCreated><Year>1997</Year><Month>02</Month><Day>25</Day></DateCreated><DateCompleted><Year>1997</Year><Month>02</Month><Day>25</Day></DateCompleted><DateRevised><Year>2016</Year><Month>11</Month><Day>24</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0364-5134</ISSN><JournalIssue CitedMedium="Print"><Volume>41</Volume><Issue>1</Issue><PubDate><Year>1997</Year><Month>Jan</Month></PubDate></JournalIssue><Title>Annals of neurology</Title><ISOAbbreviation>Ann. Neurol.</ISOAbbreviation></Journal><ArticleTitle>Which clinical sign of Parkinson's disease best reflects the nigrostriatal lesion?</ArticleTitle><Pagination><MedlinePgn>58-64</MedlinePgn></Pagination><Abstract><AbstractText>Clinical scales, based on the major signs of Parkinson's disease (PD), are commonly used to assess the effect of symptomatic treatment of PD. With the appearance of therapy aiming to rescue or protect the nigrostriatal neurons in PD, it becomes essential to define which of these signs best reflects the underlying neuronal deficit. Fluorodopa positron emission tomography has been shown to correlate with postmortem nigral cell counts. We correlated the major signs of PD with positron emission tomography results in 35 PD patients. We found that in the "practically defined off" state, (1) Purdue pegboard scores correlated best with the nigrostriatal dopaminergic deficit; (2) of the subscales of the modified Columbia score, the bradykinesia subscale correlated best; (3) rigidity and postural disturbance correlated less highly than bradykinesia, and their inclusion in a multiple regression did not improve the correlation of pegboard or bradykinesia scores alone; and (4) tremor did not correlate with the nigrostriatal dopaminergic deficit. We conclude that pegboard and bradykinesia scores represent the best clinical measures for studying the effect of treatment on the evolution of the nigrostriatal lesion of PD. Inclusion of other clinical signs provides additional information only for the study of functional impairments.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Vingerhoets</LastName><ForeName>F J</ForeName><Initials>FJ</Initials><AffiliationInfo><Affiliation>Neurodegenerative Disorders Centre and TRIUMF, University of British Columbia, Vancouver, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Schulzer</LastName><ForeName>M</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Calne</LastName><ForeName>D B</ForeName><Initials>DB</Initials></Author><Author ValidYN="Y"><LastName>Snow</LastName><ForeName>B J</ForeName><Initials>BJ</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Ann Neurol</MedlineTA><NlmUniqueID>7707449</NlmUniqueID><ISSNLinking>0364-5134</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003342" MajorTopicYN="N">Corpus Striatum</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010300" MajorTopicYN="N">Parkinson Disease</DescriptorName><QualifierName UI="Q000000981" MajorTopicYN="N">diagnostic imaging</QualifierName><QualifierName UI="Q000503" MajorTopicYN="Y">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013378" MajorTopicYN="N">Substantia Nigra</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014055" MajorTopicYN="N">Tomography, Emission-Computed</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>1997</Year><Month>1</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>1997</Year><Month>1</Month><Day>1</Day><Hour>0</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>1997</Year><Month>1</Month><Day>1</Day><Hour>0</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">9005866</ArticleId><ArticleId IdType="doi">10.1002/ana.410410111</ArticleId></ArticleIdList></PubmedData></pubmed><affiliations><list><country><li>Canada</li></country></list><tree><noCountry><name sortKey="Calne, D B" sort="Calne, D B" uniqKey="Calne D" first="D B" last="Calne">D B Calne</name><name sortKey="Schulzer, M" sort="Schulzer, M" uniqKey="Schulzer M" first="M" last="Schulzer">M. Schulzer</name><name sortKey="Snow, B J" sort="Snow, B J" uniqKey="Snow B" first="B J" last="Snow">B J Snow</name></noCountry><country name="Canada"><noRegion><name sortKey="Vingerhoets, F J" sort="Vingerhoets, F J" uniqKey="Vingerhoets F" first="F J" last="Vingerhoets">F J Vingerhoets</name></noRegion></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Canada/explor/ParkinsonCanadaV1/Data/Ncbi/Merge
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 002569 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Ncbi/Merge/biblio.hfd -nk 002569 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Canada
|area= ParkinsonCanadaV1
|flux= Ncbi
|étape= Merge
|type= RBID
|clé= pubmed:9005866
|texte= Which clinical sign of Parkinson's disease best reflects the nigrostriatal lesion?
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Ncbi/Merge/RBID.i -Sk "pubmed:9005866" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Ncbi/Merge/biblio.hfd \
| NlmPubMed2Wicri -a ParkinsonCanadaV1
| This area was generated with Dilib version V0.6.29. |  |